In this video


Cramer on how Eli Lilly could be impacted by mixed Alzheimer's drug study results

Eli Lilly said its experimental treatment for Alzheimer’s modestly slowed decline in patients over an 18-month period in a mid-stage study. Lilly has already begun a second study of the treatment. Lilly fell 5.3% in the premarket Monday. CNBC's Jim Cramer reacts to the news.
Mon, Mar 15 202110:29 AM EDT